Does Estrogen Help Frozen Shoulder? The Science Behind It

Estrogen appears to protect against frozen shoulder, but the science is still catching up to the biology. Laboratory and animal studies show that estrogen has genuine anti-fibrotic and anti-inflammatory effects on shoulder joint tissue, and the condition strikes women far more often during and after menopause, when estrogen levels plummet. Yet the clinical evidence for using estrogen therapeutically remains preliminary, with the largest study on hormone replacement therapy and frozen shoulder risk falling short of statistical significance. The connection is biologically plausible and increasingly well-mapped at a molecular level, but we are not yet at the point where a doctor can confidently prescribe estrogen to treat or prevent a frozen shoulder.

Why Frozen Shoulder Hits Women Harder After Menopause

Frozen shoulder, known clinically as adhesive capsulitis, involves the shoulder joint capsule becoming inflamed, thickened, and scarred until the joint locks up. It affects roughly two to five percent of the general population, but that number climbs sharply among people with diabetes, thyroid disorders, and autoimmune conditions.¹ The chronic inflammation triggers a cascade of events: immune signaling molecules recruit fibroblasts (the cells that lay down scar tissue), collagen piles up faster than the body can break it down, and the capsule progressively stiffens.²

What stands out in the demographics is how lopsided the timing is for women. Peri- and postmenopausal women are disproportionately affected, and their cases tend to be more severe. They often report more intense pain, longer periods of stiffness, and slower responses to physical therapy compared to younger patients or men of the same age.¹ That pattern alone does not prove estrogen is the culprit, since menopause brings a constellation of metabolic changes. But it is the observation that launched the research into estrogen’s specific role.

Estrogen Receptors Live in the Shoulder Joint

One of the strongest pieces of evidence linking estrogen to shoulder health is anatomical: the shoulder joint capsule contains estrogen receptors. Histological studies have confirmed that both major types of estrogen receptors are present in the glenohumeral joint capsule, specifically in fibroblasts, the cells lining blood vessels, and the synovial tissue that coats the inside of the joint.¹ These are not passive bystanders. When estrogen binds to these receptors, it activates genes involved in anti-inflammatory and tissue-repair processes. When estrogen levels drop, the receptors sit unbound, and those protective gene programs go quiet.

Research on the nearby rotator cuff tendons tells a similar story. In the supraspinatus tendon, cells expressed both estrogen receptor types, with statistically significant differences based on age and sex. The receptors showed up in the nuclei of tendon cells and the cells lining blood vessels, suggesting estrogen influences how these tissues maintain and repair themselves.³ The shoulder, in other words, is not just a mechanical joint. It is hormonally responsive tissue, and estrogen is one of the hormones it listens to.

How Estrogen Fights Fibrosis

The core problem in frozen shoulder is fibrosis: the unchecked buildup of scar-like tissue inside the joint capsule. Understanding how estrogen pushes back against fibrosis requires looking at what happens at the cellular level when the hormone is present versus when it is absent.

A 2025 study investigating the molecular mechanism found that both estradiol (the main circulating form of estrogen) and an activator of a specific estrogen receptor called GPER produced anti-fibrotic effects. In animal models, these compounds improved shoulder mobility, reduced the accumulation of structural proteins in the joint capsule, and decreased the activity of genes that drive fibrosis, including those responsible for fibronectin and collagen production.⁴ That study identified a specific signaling pathway through which estrogen exerts these effects, suggesting the anti-fibrotic action is not some vague side benefit but a direct, traceable molecular process.

Estrogen also influences the balance between enzymes that break down tissue and the proteins that inhibit those enzymes. In cartilage cells, estradiol significantly reduced the secretion of an enzyme responsible for degrading connective tissue, with reductions ranging from about 12 to 23 percent depending on the dose. Under inflammatory conditions, the suppression was even more pronounced, reaching roughly 38 to 39 percent.⁵ While that study focused on osteoarthritis rather than frozen shoulder specifically, the underlying tissue-remodeling machinery is shared across joints. In heart tissue, estrogen treatment restored the balance between tissue-degrading enzymes and their inhibitors, prevented unwanted collagen accumulation, and limited harmful tissue remodeling in animal models.⁶

Taken together, the picture is that estrogen acts as a brake on fibrosis through multiple routes: it dials down the inflammatory signals that start the scarring process, it reduces the production of the structural proteins that form scar tissue, and it helps maintain the balance between tissue breakdown and tissue buildup. Remove estrogen, and all three of those brakes loosen simultaneously.

The Aromatase Inhibitor Evidence

Some of the most compelling indirect evidence comes from breast cancer treatment. Aromatase inhibitors are drugs that dramatically lower estrogen levels throughout the body to starve estrogen-sensitive tumors. They are highly effective at reducing cancer recurrence, but they come with a well-recognized side effect: joint pain and stiffness, including frozen shoulder. A Mendelian randomization study examining the causal relationship between breast cancer and frozen shoulder noted that aromatase inhibitor therapy, while reducing disease recurrence risk, may also increase the risk of frozen shoulder.⁷

This is essentially a real-world experiment in estrogen deprivation. When you pharmacologically strip estrogen from the body, frozen shoulder becomes more common. That pattern is consistent with what the laboratory studies predict: without estrogen binding to receptors in the joint capsule, the anti-inflammatory and anti-fibrotic defenses weaken, and the conditions for capsular scarring improve. The aromatase inhibitor data does not prove estrogen supplementation would prevent frozen shoulder, but it strongly supports the idea that estrogen’s absence contributes to the problem.

What the Clinical Data on HRT Actually Shows

If estrogen loss promotes frozen shoulder, the logical question is whether replacing it helps. The most direct study on this looked at menopausal women at a single center and compared frozen shoulder rates between those receiving hormone replacement therapy and those who were not. Among women on HRT, about 4 percent had frozen shoulder. Among those not on HRT, the rate was roughly 7.7 percent. Women not receiving HRT had nearly double the odds of developing the condition. That sounds compelling, but the result did not reach statistical significance, meaning the difference could plausibly be due to chance.⁸

This is where the gap between biological plausibility and clinical proof becomes clear. The molecular evidence is strong. The epidemiological pattern is suggestive. The aromatase inhibitor data supports the hypothesis from the opposite direction. But the one study that directly tested whether HRT reduces frozen shoulder risk was too small or had too many confounding variables to produce a statistically definitive answer. An odds ratio of about 2.0 is the kind of effect size that would matter clinically if confirmed, but a single-center analysis with a p-value of 0.11 is not confirmation. Larger, multi-center trials would be needed to settle the question.

A systematic review examining HRT’s effects on musculoskeletal pain in menopausal women more broadly noted that while there are theoretical reasons to expect improvement, there is currently no clinical guidance recommending HRT specifically for musculoskeletal symptoms like frozen shoulder.⁹ The hypothesis exists. The guidance does not.

Estrogen Does Not Act Alone

One reason frozen shoulder is difficult to pin on a single hormone is that estrogen deficiency rarely shows up in isolation. When estrogen levels drop during menopause, a cluster of metabolic changes tends to follow: insulin resistance increases, visceral fat accumulates, and cholesterol profiles shift unfavorably. All of these changes independently promote inflammation and fibrosis.¹ A recent review went so far as to reframe frozen shoulder as a systemic immunometabolic disorder rather than a purely local joint problem, arguing that the hormonal, metabolic, and vascular disruptions of menopause converge to create the perfect conditions for capsular fibrosis.

This matters practically because it means estrogen supplementation alone might not fully protect against frozen shoulder if the accompanying metabolic dysfunction goes unaddressed. A woman with poorly controlled blood sugar, for instance, already faces elevated frozen shoulder risk through a separate inflammatory pathway. Restoring estrogen might reduce one contributor while leaving others in place. The researchers who proposed the systemic model suggested that effective prevention and treatment would need to address estrogen, insulin sensitivity, thyroid function, and vascular health together rather than targeting any single variable.¹

This interconnectedness also helps explain why the HRT study’s results were not clear-cut. If frozen shoulder arises from the intersection of multiple metabolic risk factors, and HRT only corrects one of them, you would expect a partial reduction in risk, which is broadly what the data showed. You would not necessarily expect HRT to eliminate the condition entirely.

Other Hormones in the Mix

Estrogen gets the most attention, but it is not the only hormone that affects connective tissue in and around the shoulder. Progesterone receptors have also been identified in rotator cuff tendons, with their expression varying significantly by age and sex.³ Progesterone levels also decline during menopause, and both hormones are typically included together in hormone replacement regimens for women who still have a uterus. It is difficult to separate their individual contributions in clinical studies because they tend to move in the same direction at the same time.

Relaxin, a hormone best known for loosening ligaments during pregnancy, also modifies collagen dynamics and joint laxity. Pregnancy-associated hormonal fluctuations involving estrogen, progesterone, and relaxin contribute to increased joint laxity and altered collagen dynamics.¹⁰ This is relevant because frozen shoulder is relatively uncommon during pregnancy, when estrogen and relaxin levels are both high. The protective effect may come from estrogen, relaxin, or both working together. Disentangling those contributions is an open question that current research has not resolved.

Why Standard Treatments Sometimes Fall Short in Postmenopausal Women

If you are a postmenopausal woman dealing with frozen shoulder, you may have noticed that the usual treatments seem to work more slowly for you than they appear to for others. There is a biological reason for that. Evidence from clinical and mechanistic studies indicates that estrogen signaling failure weakens the body’s anti-inflammatory, anti-fibrotic, and antioxidant defenses, predisposing postmenopausal women to more severe frozen shoulder and delayed recovery.¹ Corticosteroid injections, physical therapy, and anti-inflammatory drugs all target the downstream symptoms of inflammation and stiffness, but they do not address the upstream hormonal environment that is making the inflammation worse and harder to resolve.

This does not mean standard treatments are useless for postmenopausal women. Physical therapy remains the cornerstone of frozen shoulder management, and injections can provide meaningful pain relief that allows more effective rehabilitation. But the timeline may be longer, and the frustration is real. Acknowledging the hormonal component at least provides an explanation and opens the door to conversations with a doctor about whether hormonal factors are worth evaluating alongside the standard approach.

What a Practical Conversation With Your Doctor Looks Like

Given the current state of the evidence, estrogen therapy is not something a doctor would prescribe specifically for frozen shoulder. No clinical guidelines recommend it for this purpose, and no large trial has proven it works. But the conversation might still be worth having, especially if you are a perimenopausal or postmenopausal woman dealing with the condition alongside other menopausal symptoms like hot flashes, sleep disruption, or mood changes. If HRT is already being considered for quality-of-life reasons, knowing that it might carry a secondary benefit for joint health is useful context.

You should also be aware that if you are taking aromatase inhibitors for breast cancer and develop shoulder stiffness, frozen shoulder is a recognized complication of estrogen-suppressing therapy. Mentioning this to your oncologist may lead to earlier intervention with physical therapy rather than waiting for the condition to become fully established.

The metabolic picture matters too. Managing blood sugar, maintaining physical activity, and addressing thyroid function are all practical steps that target the broader inflammatory environment in which frozen shoulder develops. If estrogen loss is one thread in a web of metabolic changes, pulling the other threads still helps, even if the hormonal thread is left alone.

Frozen Shoulder in Men and the Estrogen Question

Men get frozen shoulder too, though less frequently than postmenopausal women. This seems to complicate the estrogen narrative, but it actually reinforces the idea that estrogen is one factor among several rather than the sole cause. Men have circulating estrogen at lower levels than premenopausal women, and their levels also decline gradually with age. Diabetes, the single strongest risk factor for frozen shoulder in any population, affects men and women roughly equally. The condition in men likely follows a more purely metabolic and inflammatory pathway, with less hormonal contribution.

There is no research investigating estrogen supplementation for frozen shoulder in men, and it would be biologically inappropriate to extrapolate from studies in menopausal women. The receptor biology is different, the baseline hormonal environment is different, and the risk factor profile skews more heavily toward diabetes and cardiovascular disease in men. For male patients, the practical implications of the estrogen research are limited, though the broader metabolic framing (controlling blood sugar, reducing inflammation, staying active) applies to everyone.

Where the Research Is Heading

The 2025 study identifying the specific molecular pathway through which estrogen exerts its anti-fibrotic effects represents a meaningful step forward.⁴ Rather than simply observing that estrogen-depleted women get more frozen shoulder, researchers can now point to a defined chain of molecular events linking estrogen receptor activation to reduced fibrosis. That kind of mechanistic clarity is what drug development needs. It opens the possibility of developing treatments that activate the same anti-fibrotic pathway without requiring systemic estrogen, which would sidestep the risks and contraindications of hormone therapy.

The GPER receptor finding is particularly interesting in this regard. GPER is a membrane-bound estrogen receptor distinct from the classical nuclear receptors, and activating it with a targeted compound produced anti-fibrotic benefits in the shoulder capsule in preclinical models.⁴ If GPER-selective drugs could be developed and delivered locally to the shoulder joint, it might be possible to get the anti-fibrotic benefit without the systemic hormonal effects. That is speculative, and it is years away from clinical reality if it happens at all, but it represents the direction the science is moving. The era of treating frozen shoulder as a purely mechanical problem that you stretch your way out of may eventually give way to approaches that address the underlying biological drivers, with hormonal signaling among them.